Orlistat-associated adverse effects and drug interactions: a critical review.
about
Does orlistat cause acute kidney injury?Weight control and prevention of metabolic syndrome by green tea.High sensitivity of Giardia duodenalis to tetrahydrolipstatin (orlistat) in vitroDietary capsaicin and its anti-obesity potency: from mechanism to clinical implications.Anti-obesogenic and antidiabetic effects of plants and mushrooms.New and emerging drug molecules against obesity.Macrocytic anemia and thrombocytopenia induced by orlistat.Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesityDoes combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Effects of anti-obesity drugs, phentermine and mahuang, on the behavioral patterns in Sprague-Dawley rat model.Nonalcoholic fatty liver disease and cardiovascular diseaseCarboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs.Dohaekseunggi-tang extract inhibits obesity, hyperlipidemia, and hypertension in high-fat diet-induced obese mice.Behavioral and pharmacologic therapies for obesity.Green tea polyphenols reduced fat deposits in high fat-fed rats via erk1/2-PPARĪ³-adiponectin pathwayThe role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agentsThe use of serotonergic drugs to treat obesity--is there any hope?Unplanned medication discontinuation as a potential pharmacovigilance signal: a nested young person cohort studyClinical and economic considerations of antiobesity treatment: a review of orlistatSafety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT studyExercise protects against obesity induced semen abnormalities via downregulating stem cell factor, upregulating Ghrelin and normalizing oxidative stressAnti-obesity effect of ethanolic extract from Cosmos caudatus Kunth leaf in lean rats fed a high fat diet.Inhibitory Activities of Cudrania tricuspidata Leaves on Pancreatic Lipase In Vitro and Lipolysis In Vivo.The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity.A Bioactivity-Based Method for Screening, Identification of Lipase Inhibitors, and Clarifying the Effects of Processing Time on Lipase Inhibitory Activity of Polygonum Multiflorum.Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.Impact of Dietary Lipids on Colonic Function and Microbiota: An Experimental Approach Involving Orlistat-Induced Fat Malabsorption in Human Volunteers.Ribose Accelerates Gut Motility and Suppresses Mouse Body Weight GainingThe prince and the pauper. A tale of anticancer targeted agents.Effect of orlistat alone or in combination with Garcinia cambogia on visceral adiposity index in obese patients.Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.Drugs in the pipeline for the obesity market.Orlistat: current status in clinical therapeutics.Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients.Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.Metabolic syndrome and bipolar disorder: what should psychiatrists know?Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus.Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.
P2860
Q26996838-B83DA0BE-C75B-42ED-A03D-120E2313874FQ27687558-62803366-7456-4541-A981-731353C5D844Q28535443-6738E037-E141-4FB0-BE2C-74750C702CF9Q30234738-34B81A5F-EA6E-4CF8-B5F4-DE2D3E86446FQ30241950-78B34F94-E81E-4B23-AB2C-C0123C102050Q30353872-8BBCE982-8A1D-420D-A156-3E07CAC862D3Q33414543-970D73D3-3085-4BF7-BDB5-994A3E0B3730Q33652893-1C8480EC-EEF2-4E01-B049-675868050B76Q33776187-FFD6B535-EF13-4FBF-9617-4FCAB3B57576Q33838889-1BC1F711-27E5-4107-A350-3AE4DA7DB7A3Q33886952-E17C12D6-CA86-4AC8-81F8-3443966E2D6FQ33916086-5B455FAF-1AEA-4173-9073-B32C3944B2ACQ34320386-A7257BBA-695C-44F3-A3B8-0709A6115F46Q34543656-1E86293C-007A-4ED9-8881-83D203D207E2Q34558750-A21E9FDC-F1DC-42EB-92C3-AB5371CBC476Q34620531-6802384E-5A04-4A57-B393-C94B25A164BEQ34712327-843DBC00-ED0B-4B94-95E1-C8DFF5EA14A2Q35110509-E0E53EF3-4B8D-400B-BC6F-7EDF5DB13D76Q35205363-726E04E0-17C2-4A9B-A40A-E886F47EAE2EQ35674320-2520B060-17C8-4F70-9EE0-27B76381D6E3Q35729223-2A766CF4-3BA1-4A21-BB83-CEE295E097CFQ36287718-89C01E9F-3C44-497A-BD52-89F0C09CCAFEQ36487686-9569321F-B60C-4E5F-89D9-9D10AC52283BQ36547159-C6E316E7-4856-46D1-B4A4-6346062525B3Q36559293-2E94E069-EA05-478E-A0A6-D64A0CADE451Q36664997-8699C167-41CC-49CF-912A-F1D3B1B9C272Q36864727-B9E1C4B3-83E2-46CD-AC4B-1A3829A0CCE4Q36911092-DEF1EE85-567C-4067-88B9-D5620B0254D8Q37042365-43B9B1DC-6A14-487D-B48E-760BDEF392DCQ37334443-4D19E821-4F4A-42C0-95AA-3F14D80C09EDQ37359377-05EFF3B7-F341-4C55-A5C5-0B95F7C0E694Q37404241-FD658CF1-87CB-45F6-A84C-7DA847C47EDAQ37649644-2F69156E-CC6B-4AC5-8BE2-F39CC3181695Q37669343-77B0D09D-4507-424E-8FA4-BC23B4D28387Q37831334-41644F38-FF4D-4E9D-B92E-735DE1AD4763Q37857866-BBC2A221-9985-490E-9F10-FF2DEC654435Q37954425-DEBB8325-60BC-47A5-8B91-D2479D027E3EQ38207128-49B240EC-C977-47BB-BFEC-99526747D032Q38259933-AA3A44E9-02F4-4652-898C-18769778EAA4Q38308961-D1DC0B45-411D-4099-B886-D53786858CE5
P2860
Orlistat-associated adverse effects and drug interactions: a critical review.
description
2008 nĆ® lÅ«n-bĆ»n
@nan
2008 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Õ
ÕøÖÕ¶ÕøÖÕ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2008 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ°ÕøÖÕ¶Õ¾Õ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2008幓ć®č«ę
@ja
2008幓č«ę
@yue
2008幓č«ę
@zh-hant
2008幓č«ę
@zh-hk
2008幓č«ę
@zh-mo
2008幓č«ę
@zh-tw
2008幓č®ŗę
@wuu
name
Orlistat-associated adverse effects and drug interactions: a critical review.
@ast
Orlistat-associated adverse effects and drug interactions: a critical review.
@en
Orlistat-associated adverse effects and drug interactions: a critical review.
@nl
type
label
Orlistat-associated adverse effects and drug interactions: a critical review.
@ast
Orlistat-associated adverse effects and drug interactions: a critical review.
@en
Orlistat-associated adverse effects and drug interactions: a critical review.
@nl
prefLabel
Orlistat-associated adverse effects and drug interactions: a critical review.
@ast
Orlistat-associated adverse effects and drug interactions: a critical review.
@en
Orlistat-associated adverse effects and drug interactions: a critical review.
@nl
P2093
P1433
P1476
Orlistat-associated adverse effects and drug interactions: a critical review.
@en
P2093
Christos S Derdemezis
Eleni S Nakou
Irene F Gazi
Moses S Elisaf
Theodosios D Filippatos
P356
10.2165/00002018-200831010-00005
P577
2008-01-01T00:00:00Z
P5875
P6179
1017962750